ClinicaliQ Trial Snapshot
- Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease — Recruiting • Diabetes / Metabolic • NCT04873258.
- What is being tested: Development and validation of a non-invasive screening tool to predict metabolic dysfunction-associated steatotic liver disease (MASLD), potentially replacing the need for invasive liver biopsy diagnosis.
- Patient eligibility overview: The study recruits adults with metabolic risk factors (obesity, type 2 diabetes, dyslipidaemia) and/or imaging evidence of liver steatosis, establishing baseline structural and functional liver parameters across disease severity.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A generic screening study to establish structural and/or functional baselines of specific organs.
Eligibility Snapshot
- : 1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations. 3. An understanding, ability and willingness to fully comply with project procedures and restrictions. For PART B only: 1. With a known history of MASLD as evidenced either of: 1. GP diagnosis on HCF 2. Documented Fibroscan or liver US demonstrating MASLD
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.